Marshall Wace
NTGN

Marshall Wace’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Marshall Wace’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-21,809
Closed -$38K – 2255
2019
Q3 		$38K Buy
+21,809
New +$66.4K ﹤0.01% 1532

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's NTGN Position: Q4 2019 in Review

Marshall Wace sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q4 2019, closing a stake of 21,809 shares — an estimated $38K sold.

Marshall Wace first reported a position in NTGN in Q3 2019 and held it in 1 quarter. The position peaked at $38K in Q3 2019. 46 funds tracked by Wall St. Rank hold NTGN as of Q4 2019.

  • Marshall Wace reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace sold 21,809 Neon Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $38K.
  • Marshall Wace first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Marshall Wace's Neon Therapeutics, Inc. Common Stock position peaked at $38K in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Marshall Wace's 13F filing for Q4 2019, filed 14 Feb 2020.